CLINICAL ROLE -
FDA Approves CAR T-Cell Therapy for Large B-Cell Lymphoma
The approval includes the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Read More
FDA Greenlights CAR T Therapy for Large B-Cell Lymphoma
Tisagenlecleucel (Kymriah, Novartis) is now approved for the treatment of diffuse large B-cell (DLBCL) lymphoma, as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
FDA OKs Combo Adjuvant Therapy for BRAF V600-Mutant Melanoma
Trametinib plus dabrafenib is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection.
Novel Targeted Therapy Effective Against Lung, Thyroid Cancers in Preclinical Trial
BLU-667 is being investigated for the treatment of cancers caused by an alteration in the receptor tyrosine kinase.
Study Sheds Light on How HIV Evades the Immune System
HIV targets and disables a pathway involved in blocking viral activity and clearing infection.
Human Drug Trials Negatively Impacted by Poor Reporting, Design of Animal Studies
Poor study design and reporting in animal research compromises the ethical review of proposed human drug trials.
New Analysis Further Supports Canagliflozin
In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.
Breakthrough Technique Improves Precision of Gene-Editing Technology
A synthetic bridged nucleic acid was found to greatly improve the accuracy of gene-editing technology, which could potentially lead to new therapies for genetic diseases.
New Technology Could Advance Precision Medicine for Cancer, Neurological Disorders
The new method indexes thousands of cells simultaneously and could potentially improve understanding of various diseases at a molecular level.
Breast Cancer Therapy and Heart Disease: Attentive Care Prevents Risk
In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.
Out-of-Pocket Expenses of Chronic Heart Disease Burdensome for Low-Income Families
Low-income families can experience catastrophic financial burden from cumulative out-of-pocket expenses for atherosclerotic cardiovascular disease treatments.
Drug Demonstrates Efficacy in Patients with Episodic Migraines
Amgen’s erenumab (Aimovig) achieved positive results in the first-of-its-kind phase 3b LIBERTY trial for the treatment of patients with episodic migraines who had previously failed 2 to 4 preventive treatments.
Migraine Drug Demonstrates Efficacy in Patients with Multiple Treatment Failures
Patients treated with erenumab had nearly 3-fold higher odds of having their migraine days cut by at least 50%.
Study: Cancer Outcomes Worse for Patients Who Wait Longer for Diagnostic Testing
A review found an elevated risk of cancer progression with increasing wait time between positive screening and start of diagnostic testing.
Nivolumab Increases Anti-Tumor Immunity, Reduces Post-Surgery Relapse Rate
Nivolumab showed major tumor responses in early stage lung cancer patients and an increase in anti-tumor T-cells that remained after the tumor was removed.
ACR: CMS Rule on Essential Health Benefit Coverage Could Harm Patient Access to Rheumatology Care
The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.
FDA Accepts Supplemental Biologics License Application for Nivolumab for Third-Line Small Cell Lung Cancer Treatment
The FDA has granted priority review to the application for the treatment of patients with small cell lung cancer whose disease has progressed after 2 or more prior lines of therapy.
Merck Announces Positive Phase 3 Results for Keytruda as Lung Cancer Therapy
Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.
FDA Grants Breakthrough Therapy Designation to Hemlibra for Hemophilia A Without Inhibitors
Emicizumab-kxwh (Hemlibra, Genentech) is the first medication to show superior efficacy compared with prior factor VIII prophylaxis in intra-patient comparisons.
Survey: Many Americans Unaware of Cancer Drug Shortages
Most of the survey respondents were unaware of oncology drug shortages but would want to be told about any therapy substitutions caused by short supply.
New Opioid Prescribing Guidance Targets Inpatient Acute Pain Management
Until now, there has been little guidance on the safe prescribing of opioids in the inpatient, non-operative setting.
Inlyta Fails to Demonstrate Efficacy in Patients at High Risk of Recurrent Renal Cell Carcinoma
In its phase 3 trial, Pfizer’s axitinib (Inlyta) did not achieve disease-free survival in patients at high risk of recurrent renal cell carcinoma after nephrectomy.
Coffee Filter Method Yields Cheaper Production of Cancer Drug Candidate
The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study
FDA Approves First-Line Treatment Combo for Advanced Renal Cell Carcinoma
Opdivo and Yervoy combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced RCC.
FDA Issues Guidances to Advance Development of Novel Genetic-Based Tests
The guidances provide recommendations for the development and validation of tests that use next generations sequencing.
Second-Line Liver Cancer Treatments Shows Positive Results in Phase 3 Study
Ramucirumab improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who have a high alpha-fetoprotein.
Rheumatoid Arthritis Treatment Achieves All Primary Endpoints in Phase 3 Trial
Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.
PBM Transparency, DIR Fees Top Priorities for Pharmacists on Capitol Hill
Community pharmacists urge Congress to support 3 priority bills that create transparency for pharmacy benefit managers and improve patient access.
Drug Combo Shows Promise Treating Non-Small Cell Lung Cancer
The EGFR/TNF inhibitor treatment effectively blocks the tumor necrosis factor escape route for non-small cell lung cancer.
Improvement Needed to Reduce Hepatitis B Virus Prevalence Worldwide
Access to diagnosis and treatment must be improved worldwide to meet target goals for the elimination of viral hepatitis.